Key result
Landmark cardiogenic shock trial criteria exclude most real-world tMCS patients, revealing a substantial evidence gap.
Current landmark trials for temporary mechanical circulatory support in cardiogenic shock lack generalizability to the broader real-world patient population, necessitating enhanced registry enrollment and innovative analytic strategies.
Answers are grounded in this paper and cite their sources.
Mandates caution extrapolating landmark CS MCS trials to most real-world patients; leaves open optimal support strategies and demands inclusive registries.
Patients meeting the landmark CS trial criteria represent a small, high-risk subset of the real-world CS population, highlighting a substantial evidence gap for the majority of CS patients receiving tMCS in clinical practice. Enhancing registry enrollment of specific CS subsets and adopting innovative analytic strategies could bridge gaps between randomized controlled trials findings and real-world applicability.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a review in Cardiogenic shock (CS). Temporary mechanical circulatory support (tMCS) was evaluated. Landmark cardiogenic shock trial criteria capture only a small, high-risk subset of the real-world population, revealing a substantial evidence gap for most patients receiving temporary MCS.
Synapse has enriched 10 related papers. Consider them for comparative context: